WO2011117875A1 - Salts of fluvastatin and process for the preparation of substantially amorphous fluvastatin sodium - Google Patents
Salts of fluvastatin and process for the preparation of substantially amorphous fluvastatin sodium Download PDFInfo
- Publication number
- WO2011117875A1 WO2011117875A1 PCT/IN2010/000189 IN2010000189W WO2011117875A1 WO 2011117875 A1 WO2011117875 A1 WO 2011117875A1 IN 2010000189 W IN2010000189 W IN 2010000189W WO 2011117875 A1 WO2011117875 A1 WO 2011117875A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- fluvastatin
- solvent
- strontium
- barium
- methyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D209/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an alkyl or cycloalkyl radical attached to the ring nitrogen atom
Definitions
- the present invention provides barium salt of fluvastatin, process for its preparation and pharmaceutical composition comprising it.
- the present invention also provides strontium salt of fluvastatin, process for its preparation and pharmaceutical composition comprising it.
- the present invention further provides novel process for the preparation of substantially amorphous fluvastatin sodium.
- Fluvastatin also known as racemic mixture of (3R,5S) and (3S,5R) erythro-7-[3- (4-fluorophenyl)- 1 -(propan-2-yl)- 1 H-indol-2-yl] -3 ,5-dihydroxyhept-6-enoic acid, as well as its sodium salt, were disclosed in US Patent no. 4,739,073 (herein after referred to '073 patent). Fluvastatin was represented by the following structure:
- Fluvastatin sodium was a hypercholesterolemic, hyperlipoproteinemic and antiatherosclerotic agent and was therapeutic proteosome inhibitor available in the market under the brand name "LESCOL ® " in the form of oral dosage.
- Example 6(a) of the ⁇ 73 patent a methyl ester precursor of ( ⁇ ) fluvastatin was hydrolyzed with sodium hydroxide in methanol, which yielded, after evaporation of the methanol, crude fluvastatin sodium.
- Example 6(b) the fluvastatin methyl ester was hydrolyzed with sodium hydroxide in ethanol. After evaporation of the ethanol, the residue was taken up in water and lyophilized. The lyophilized product had a melting point range of 194°C to 197°C.
- the sodium salt was prepared by ring opening of fluvastatin lactone with sodium hydroxide in ethanol.
- Fluvastatin sodium was specifically disclosed in US Patent no. 5,354,772.
- Polymorphism is defined as "the ability of a substance to exist as two or more crystalline phases that have different arrangement and/or conformations of the molecules in the crystal Lattice.
- polymorphs are different crystalline forms of the same pure substance in which the molecules have different arrangements and/or different configurations of the molecules.
- Different polymorphs may differ in their physical properties such as melting point, solubility, X-ray diffraction patterns, etc. Although those differences disappear once the compound is dissolved, they can appreciably influence pharmaceutically relevant properties of the solid form, such as handling properties, dissolution rate and stability. Such properties can significantly influence the processing, shelf life, and commercial acceptance of a polymorph.
- Polymorphic forms of a compound can be distinguished in the laboratory by analytical methods such as X-ray diffraction (XRD), Differential Scanning Calorimetry (DSC) and Infrared spectrometry (IR).
- XRD X-ray diffraction
- DSC Differential Scanning Calorimetry
- IR Infrared spectrometry
- Solvent medium and mode of crystallization play very important role in obtaining a crystalline form over the other.
- Salts of fluvastatin can exist in different polymorphic forms, which differ from each other in terms of stability, physical properties, spectral data and methods of preparation.
- U.S. Patent no. 6,124,340 disclosed the use of lyophilization to prepare fluvastatin sodium, which leads to a mixture of crystalline as well as amorphous material.
- the amorphous form is designated as form A and crystalline form which is a monohydrate, is designated as form B.
- substantially amorphous fluvastatin sodium can be prepared by suspending crude fluvastatin sodium having a moisture content about 4.0% w/w with tetrahydrofiu-an to form a mixture, contacting the mixture with tetrahydrofuran and removing the solvent from the mixture to form a resultant mass, the resultant mass was added with one or more organic solvents such as cyclohexane, n-heptane, dichloromethane, diisopropyl ether or hexane at room temperature and isolating.
- organic solvents such as cyclohexane, n-heptane, dichloromethane, diisopropyl ether or hexane at room temperature and isolating.
- another process of substantially amorphous fluvastatin sodium can be prepared by dissolving fluvastatin sodium having a moisture content of about 5% w/w or less in an organic solvent such as methanol and removing the organic solvent from the solution thereof.
- another process of substantially amorphous fluvastatin sodium having 15% or less of crystallinity can be prepared by dissolving fluvastatin sodium having a moisture content of about 5% w/w or less in an organic solvent such as methanol and removing the organic solvent from the solution thereof.
- European patent application no. 1790635 disclosed a process for the preparation of amorphous fluvastatin sodium which comprises dissolving fluvastatin sodium in 1,4- dioxane, cooling the solution to induce precipitation of amorphous fluvastatin sodium and separating the amorphous fluvastatin sodium from the 1,4-dioxane.
- another process for the preparation of amorphous fluvastatin sodium which comprises suspending a 1,4-dioxane of fluvastatin in cyclohexane, adding about one molar equivalent of sodium hydroxide in a minimum of methanol and isolating the amorphous fluvastatin sodium.
- PCT application publication no. WO 2006/038219 described a process for the preparation of amorphous form of fluvastatin sodium can be prepared by dissolving the sodium fluvastatin in methanol followed by stirring, concentrating the methanol extracts to get a residue and isolating the residue to obtain amorphous form of fluvastatin sodium.
- One object of the present invention is to provide a barium salt of fluvastatin, process for its preparation and pharmaceutical composition comprising it.
- Another object of the present invention is to provide a strontium salt of fluvastatin, process for its preparation and pharmaceutical composition comprising it.
- the salt of the present invention may also serve as intermediates for preparation of substantially amorphous fluvastatin sodium and other polymorphs of fluvastatin sodium.
- Yet another object of the present invention is to provide a novel process for the preparation of substantially amorphous fluvastatin sodium.
- the present invention provides a barium salt of fluvastatin, that is, fluvastatin barium.
- the present invention provides a process for the preparation of fluvastatin barium, which comprises reacting methyl( ⁇ )-erythro-(E)-3,5-dihydroxy-7-[3'- (4"-fluorophenyl)-l'-(l"-methylethyl)indol-2'-yl]hept-6-enoate with barium hydroxide in suitable solvent to form fluvastatin barium.
- the present invention provides a pharmaceutical composition comprising fluvastatin barium and a pharmaceutically acceptable excipient.
- the present invention provides a strontium salt of fluvastatin, that is, fluvastatin strontium.
- the present invention provides a process for the preparation of fluvastatin strontium, which comprises reacting methyl( ⁇ )-erythro-(E)-3,5-dihydroxy-7- [3 '-(4"-fluorophenyl)- 1 '-( 1 "-methylethyl)indol-2'-yl]hept-6-enoate with strontium hydroxide in suitable solvent to form fluvastatin strontium.
- the present invention provides a pharmaceutical composition comprising fluvastatin strontium and a pharmaceutically acceptable excipient.
- the present invention provides a novel process for the preparation substantially amorphous fluvastatin sodium, which comprises:
- step (a) b) mixing one or more hydrocarbon solvents to the solution obtained in step (a) at above 35°C;
- Figure 1 is X-ray powder diffraction spectrum of substantially amorphous fluvastatin barium.
- Figure 2 is X-ray powder diffraction spectrum of substantially amorphous fluvastatin strontium.
- Figure 3 is X-ray powder diffraction spectrum of substantially amorphous fluvastatin sodium.
- X-ray powder diffraction spectrum was measured on a bruker axs D8 advance X- ray powder diffractometer having a copper- ⁇ radiation.
- Approximately 1 gm of sample was gently flattered on a sample holder and scanned from 2 to 50 degrees two-theta, at 0.02 degrees to theta per step and a step of 10.4 seconds.
- the sample was simply placed on the sample holder.
- the sample was rotated at 30 rpm at a voltage 40 KV and current 35 mA.
- a barium salt of fluvastatin that is, fluvastatin barium.
- fluvastatin barium as used herein means any salt comprising fluvastatin anions and barium cations.
- the fluvastatin barium may preferably be a solid such as amorphous or crystalline and more preferable solid is substantially amorphous fluvastatin barium.
- substantially amorphous fluvastatin barium refers to amorphous fluvastatin barium having about 35% w/w or less cr stallinity.
- the powdered x-ray diffractogram (PXRD) of substantially amorphous fluvastatin barium is shown in figure 1.
- a process for the preparation of fluvastatin barium which comprises reacting methyl( ⁇ )-erythro- (E)-3,5-dihydroxy-7-[3'-(4"-fluorophenyl)-l'-(l"-methylethyl)indol-2'-yl]hept-6-enoate with barium hydroxide in suitable solvent to form fluvastatin barium.
- fluvastatin barium may be prepared by a process which comprises reacting fluvastatin or its sodium salt with barium hydroxide in suitable solvent to form fluvastatin barium.
- the suitable solvent used in the process may preferably be a solvent or mixture of solvents selected from the group consisting of water; an alcoholic solvent such as methanol, ethanol and isopropyl alcohol; an ester solvent such as ethyl acetate, methyl acetate, isopropyl acetate, tert-butyl methyl acetate and ethyl formate; acetonitrile; dimethylformamide; dimethylsulf oxide; an aromatic hydrocarbon solvent such as benzene, toluene and xylene; a halogenated hydrocarbon solvent such as methylene chloride, chloroform,' carbontetrachloride and ethylene dichloride; a ketonic solvent such as acetone, methyl ethyl ketone, methyl isobutyl ketone and diethyl ketone; an ether solvent such as tetrahydrofuran, 1,4-dioxane, tert-butyl methyl ether
- a pharmaceutical composition that comprises fluvastatin barium and pharmaceutically acceptable carriers, diluents or excipients and optionally other therapeutic ingredients.
- the salt may preferable be conveniently formulated into tablets, capsules, suspensions, dispersions, injectables and other pharmaceutical forms.
- a strontium salt of fluvastatin that is, fluvastatin strontium.
- fluvastatin strontium as used herein means any salt comprising fluvastatin anions and strontium cations.
- the fluvastatin strontium may preferably be a solid such as amorphous or crystalline and more preferable solid is substantially amorphous fluvastatin strontium.
- substantially amorphous fluvastatin strontium refers to amorphous fluvastatin strontium having about 50% w/w or less crystallinity
- the powdered x-ray diffractogram (PXRD) of substantially amorphous fluvastatin strontium is shown in figure 2.
- a process for the preparation of fluvastatin strontium which comprises reacting methyl( ⁇ )-erythro- (E)-3,5-dihydroxy-7-[3'-(4"-fluorophenyl)- -(r'-methylethyl)indol-2'-yl]hept-6-enoate with strontium hydroxide in suitable solvent to form fluvastatin strontium.
- fluvastatin strontium may be prepared by a process which comprises reacting fluvastatin or its sodium salt with strontium salt of an acid in suitable solvent to form fluvastatin strontium.
- the suitable solvent used in the process may preferably be a solvent or mixture of solvents selected from the group consisting of water; an alcoholic solvent such as methanol, ethanol and isopropyl alcohol; an ester solvent such as ethyl acetate, methyl acetate, isopropyl acetate, tert-butyl methyl acetate and ethyl formate; acetonitrile; dimethylformamide; dimethylsulfoxide; an aromatic hydrocarbon solvent such as benzene, toluene and xylene; a halogenated hydrocarbon solvent such as methylene chloride, chloroform, carbontetrachloride and ethylene dichloride; a ketonic solvent such as acetone, methyl ethyl ketone, methyl isobutyl ketone and diethyl ketone; an ether solvent such as tetrahydrofuran, 1,4-dioxane, tert-butyl methyl ether and
- a pharmaceutical composition that comprises fluvastatin strontium and pharmaceutically acceptable carriers, diluents or excipients and optionally other therapeutic ingredients.
- the salt may preferable be conveniently formulated into tablets, capsules, suspensions, dispersions, injectables and other pharmaceutical forms.
- step (a) b) mixing one or more hydrocarbon solvents to the solution obtained in step (a) at above 35°C;
- substantially amorphous fluvastatin sodium refers to amorphous fluvastatin sodium having about 25% w/w or less crystallinity.
- the ether solvent used in step (a) may preferably be a solvent or mixture of solvents selected from tetrahydrofuran, methyl tetrahydrofuran, methyl tert-butyl ether, ethyl tert-butyl ether, 1 ,4-dioxane, diisopropyl ether, diethyl ether and tetrahydropyran. More preferable ether solvent is tetrahydrofuran and methyl tetrahydrofuran.
- reaction in step (b) may preferably be carried out at 40°C to boiling point of solvent or solvents and more preferably at 40 to 90°C.
- the hydrocarbon solvents used in step (b) may preferably be selected from cyclohexane, n-hexane, heptane, benzene, toluene and xylene. More preferable hydrocarbon solvents are cyclohexane and heptane. Order of addition of hydrocarbon solvent or solvents to the ether solution are not critical. The hydrocarbon solvent or solvents may be added to the ether solution or the ether solution may be added to hydrocarbon solvent or solvents.
- the isolation of substantially amorphous fluvastatin sodium may preferably be performed by conventional techniques such as centrifugation and filtration.
- Methyl( ⁇ )-erythro-(E)-3,5-dihydroxy-7-[3'-(4 -fluorophenyl)-l'-(r'-methylethyl) indol-2'-yl]hept-6-enoate (100 gm) was added to methanol (1000 ml) and stirred at 25 to 30°C.
- Barium hydroxide octahydrate (40 gm) was added to the above mixture at 25 to 30°C. The reaction mixture was stirred for 4 hours at 25 to 30°C, and then filtered. The solid obtained was washed with methanol and dried at 45 to 50°C for 4 hours to obtain 80 gm of substantially amorphous fluvastatin barium.
- Fluvastatin (10 gm) was added to ethanol (100 ml) and barium hydroxide octahydrate (4 gm) at 25 to 30°C. The reaction mixture was stirred for 4 hours at 25 to 30°C, and then filtered. The solid obtained was washed with ethanol and dried at 45 to 50°C for 4 hours to obtain 8.5 gm of substantially amorphous fluvastatin barium.
- Fluvastatin sodium 100 gm was dissolved in methanol (1000 ml) at 25 to 30°C to get a clear solution.
- Barium hydroxide octahydrate 40 gm was slowly added to the above solution at 25 to 30°C.
- the reaction mixture was stirred for 4 hours at 25 to 30°C, the obtained solid was filtered and washed with water. The solid was dried at 45 to 50°C for 4 hours to obtain 85 gm of substantially amorphous fluvastatin barium.
- Example 4 Preparation of substantially amorphous fluvastatin strontium Methyl( ⁇ )-erythro-(E)-3,5-dihydroxy-7-[3'-(4"-fluorophenyl)-r-(r'-methylethyl) indol-2'-yl]hept-6-enoate (100 gm) was added to methanol (1000 ml) and stirred at 25 to 30°C.
- Strontium hydroxide octahydrate (67 gm) was added to the above mixture at 25 to 30°C. The reaction mixture was stirred for 10 hours at 25 to 30°C, and then filtered. The solid obtained was washed with methanol and dried at 40 to 45 °C for 5 hours to obtain 73 gm of substantially amorphous fluvastatin strontium.
- Fluvastatin (10 gm) was added to ethanol (100 ml) and strontium hydroxide octahydrate (6 gm) at 25 to 30°C. The reaction mixture was stirred for 10 hours at 25 to 30°C, and then filtered. The solid obtained was washed with ethanol and dried at 40 to 45°C for 5 hours to obtain 7 gm of substantially amoiphous fluvastatin strontium.
- Fluvastatin sodium (100 gm) was dissolved in methanol (1000 ml) at 25 to 30°C to get a clear solution.
- Strontium hydroxide octahydrae (65 gm) was slowly added to the above solution at 25 to 30°C.
- the reaction mixture was stirred for 10 hours at 25 to 30°C, the obtained solid was filtered and washed with water. The solid was dried at 40 to 45°C for 5 hours to obtain 85 gm of substantially amorphous fluvastatin strontium.
- Example 7 Preparation of substantially amorphous fluvastatin sodium
- Methyl( ⁇ )-erythro-(E)-3 ,5 -dihydroxy-7- [3 '-(4"-fluorophenyl)- ⁇ -( 1 "-methylethyl) indol-2'-yl]hept-6-enoate 100 gm
- methanol 300 ml
- sodium hydroxide 10 gm
- water 25 ml
- Methylene chloride 1000 ml was added to the solution and distilled off the solvent at 40°C under vacuum and then co-distilled with methyl tetrahydrofuran under nitrogen atmosphere to obtain residue.
- Methyl( ⁇ )-erythro-(E)-3,5-dihydroxy-7-[3'-(4"-fluorophenyl)-l , -(l"-methylethyl) indol-2'-yl]hept-6-enoate 100 gm
- methanol 300 ml
- sodium hydroxide 10 gm
- water 25 ml
- the solid obtained was washed with a mixture of heptane and cyclohexane and then dried at 90°C under vacuum for 10 hours to obtain 80 gm of substantially amorphous fluvastatin sodium (Content of residual solvents: 120 ppm of cyclohexane; 195 ppm of heptane).
- Fluvastatin sodium crystalline form B (100 gm) was dissolved in methylene chloride (1000 ml) at room temperature. The contents were heated to reflux and were added methanol (250 ml) to obtain a solution. The solution was stirred for 15 minutes and filtered on hiflo-bed at 50°C, washed with methylene chloride. The filtrate obtained was distilled at below 40°C and co-distilled with tetrahydrofuran to obtain a residue. To the residue were added tetrahydrofuran (300 ml). The mixture of cyclohexane (750 ml) and heptane (750 ml) was heated to 80 to 85°C and then slowly added above reaction mass to this solution.
- Example 10 The contents were maintained for 30 minutes at 80 to 85°C and then cooled to room temperature, maintained for 15 minutes at room temperature. The solid obtained was collected by filtration, washed with a mixture of cyclohexane and heptane and then dried at 100°C under vacuum for 15 hours to obtain 90 gm of substantially amorphous fluvastatin sodium (Residual solvents are absent).
- Example 10
- Example 9 was repeated using fluvastatin sodium crystalline form XIV instead of fluvastatin sodium crystalline form B to obtain substantially amorphous fluvastatin sodium.
- Example 9 was repeated using fluvastatin sodium crystalline form XXVI instead of fluvastatin sodium crystalline form B to obtain substantially amorphous fluvastatin sodium.
- Fluvastatin barium (80 gm) was stirred with water (500 ml) and methylene chloride (1000 ml) at 25 to 30°C.
- the pH of the reaction mass was adjusted to 7.0 with hydrochloric acid (50%, 50 ml) and layers were separated.
- the organic layer was washed with sodium chloride (10%, 500 ml). Distilled off the solvent at 40°C under vacuum and co-distilled with tetrahydrofuran to obtain a residue.
- To the residue was added tetrahydrofuran (200 ml) and sodium hydroxide (7 gm) and then stirred for 30 minutes.
- Fluvastatin strontium 50 gm was stirred with water (300 ml) and methylene chloride (600 ml) at 25 to 30°C. The pH of the reaction mass was adjusted to 7.0 with hydrochloric acid (50%, 50 ml). The organic layer was separated and washed with sodium chloride. Distilled off the solvent at 40 C under vacuum and co-distilled with tetrahydrofuran to obtain a residue. To the residue was added tetrahydrofuran (120 ml) and sodium hydroxide (4 gm) and then stirred for 30 minutes.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Indole Compounds (AREA)
Abstract
The present invention provides barium salt of fluvastatin, process for its preparation and pharmaceutical composition comprising it. The present invention also provides strontium salt of fluvastatin, process for its preparation and pharmaceutical composition comprising it. The present invention further provides novel process for the preparation of substantially amorphous fluvastatin sodium.
Description
SALTS OF FLUVASTATIN AND PROCESS FOR THE PREPARATION OF
SUBSTANTIALLY AMORPHOUS FLUVASTATIN SODIUM
Field of the Invention
The present invention provides barium salt of fluvastatin, process for its preparation and pharmaceutical composition comprising it. The present invention also provides strontium salt of fluvastatin, process for its preparation and pharmaceutical composition comprising it. The present invention further provides novel process for the preparation of substantially amorphous fluvastatin sodium.
Background of the Invention
Fluvastatin, also known as racemic mixture of (3R,5S) and (3S,5R) erythro-7-[3- (4-fluorophenyl)- 1 -(propan-2-yl)- 1 H-indol-2-yl] -3 ,5-dihydroxyhept-6-enoic acid, as well as its sodium salt, were disclosed in US Patent no. 4,739,073 (herein after referred to '073 patent). Fluvastatin was represented by the following structure:
Fluvastatin sodium was a hypercholesterolemic, hyperlipoproteinemic and antiatherosclerotic agent and was therapeutic proteosome inhibitor available in the market under the brand name "LESCOL®" in the form of oral dosage.
According to Ό73 patent was described process for the preparation of fluvastatin and its sodium salt. In Example 6(a) of the Ό73 patent, a methyl ester precursor of (±) fluvastatin was hydrolyzed with sodium hydroxide in methanol, which yielded, after evaporation of the methanol, crude fluvastatin sodium. In Example 6(b), the fluvastatin methyl ester was hydrolyzed with sodium hydroxide in ethanol. After evaporation of the
ethanol, the residue was taken up in water and lyophilized. The lyophilized product had a melting point range of 194°C to 197°C. In Example 8, the sodium salt was prepared by ring opening of fluvastatin lactone with sodium hydroxide in ethanol.
Fluvastatin sodium was specifically disclosed in US Patent no. 5,354,772.
Polymorphism is defined as "the ability of a substance to exist as two or more crystalline phases that have different arrangement and/or conformations of the molecules in the crystal Lattice. Thus, in the strict sense, polymorphs are different crystalline forms of the same pure substance in which the molecules have different arrangements and/or different configurations of the molecules". Different polymorphs may differ in their physical properties such as melting point, solubility, X-ray diffraction patterns, etc. Although those differences disappear once the compound is dissolved, they can appreciably influence pharmaceutically relevant properties of the solid form, such as handling properties, dissolution rate and stability. Such properties can significantly influence the processing, shelf life, and commercial acceptance of a polymorph. It is therefore important to investigate all solid forms of a drug, including all polymorphic forms, and to determine the stability, dissolution and flow properties of each polymorphic form. Polymorphic forms of a compound can be distinguished in the laboratory by analytical methods such as X-ray diffraction (XRD), Differential Scanning Calorimetry (DSC) and Infrared spectrometry (IR).
Solvent medium and mode of crystallization play very important role in obtaining a crystalline form over the other.
Salts of fluvastatin can exist in different polymorphic forms, which differ from each other in terms of stability, physical properties, spectral data and methods of preparation.
PCT application publication no. 2004/113292 disclosed fluvastatin sodium crystal forms XIV, LXXIII, LXXIX, LXXX and LXXXVII.
PCT application publication no. 2004/113292 described various polymorphic forms of fluvastatin sodium and process for their preparation. The Publication described the formation of several polymorphic forms of fluvastatin sodium, which were designated forms I, II, III, IV, IV-1, V, VI, VII, IX, IX-1, XI, XI-2, XII, XIII, XVI,
XVII, XVIII, XIX, XIX- 1, XX, XXII, XXIII, XXIV, XXVI, XXVII, XXIX, XXX,
XXXI, XXXIII, XXXIV, XXXV, XXXVI, XXXVII, XXXVIII, XXXIX, XLI, XLII, XLIII, XLIV, XLV, XL VI, XL VII, XLVIII, XLIX, L, LI, LIII, LIV, LV, LVI, LVII, LVIII, LX, LXIV, LXV, LXVI, LXVII, LXVIII, LXIX, LXX, LXXI, LXXII, LXXIV, LXXV, LXXVI, LXXVII, LXXVIII, XC, XCI, XCII, XCIII, XCIV, XCV, XCVI, XCVII, XCVIII, XCIX, C, CI, CII, CHI, CIV, and CV.
U.S. Patent no. 6,124,340 disclosed the use of lyophilization to prepare fluvastatin sodium, which leads to a mixture of crystalline as well as amorphous material. The amorphous form is designated as form A and crystalline form which is a monohydrate, is designated as form B.
PCT application publication no. WO 2006/030304 (herein after referred to '304 patent) disclosed in substantially amorphous fluvastatin sodium having about 15% or less of crystallinity, amorphous form R-6 of fluvastatin sodium and anhydrous crystalline fluvastatin sodium.
According to the '304 patent, substantially amorphous fluvastatin sodium can be prepared by suspending crude fluvastatin sodium having a moisture content about 4.0% w/w with tetrahydrofiu-an to form a mixture, contacting the mixture with tetrahydrofuran and removing the solvent from the mixture to form a resultant mass, the resultant mass was added with one or more organic solvents such as cyclohexane, n-heptane, dichloromethane, diisopropyl ether or hexane at room temperature and isolating.
According to the '304 patent, another process of substantially amorphous fluvastatin sodium can be prepared by dissolving fluvastatin sodium having a moisture content of about 5% w/w or less in an organic solvent such as methanol and removing the organic solvent from the solution thereof.
According to the '304 patent, another process of substantially amorphous fluvastatin sodium having 15% or less of crystallinity can be prepared by dissolving fluvastatin sodium having a moisture content of about 5% w/w or less in an organic solvent such as methanol and removing the organic solvent from the solution thereof.
European patent application no. 1790635 disclosed a process for the preparation of amorphous fluvastatin sodium which comprises dissolving fluvastatin sodium in 1,4- dioxane, cooling the solution to induce precipitation of amorphous fluvastatin sodium and separating the amorphous fluvastatin sodium from the 1,4-dioxane. According to
the patent, another process for the preparation of amorphous fluvastatin sodium which comprises suspending a 1,4-dioxane of fluvastatin in cyclohexane, adding about one molar equivalent of sodium hydroxide in a minimum of methanol and isolating the amorphous fluvastatin sodium.
PCT application publication no. WO 2006/038219 described a process for the preparation of amorphous form of fluvastatin sodium can be prepared by dissolving the sodium fluvastatin in methanol followed by stirring, concentrating the methanol extracts to get a residue and isolating the residue to obtain amorphous form of fluvastatin sodium.
It has been found that the amorphous fluvastatin sodium produced according to the prior art procedures are contaminated with the residual solvents such as cyclohexane, n-heptane, dichloromethane, diisopropyl ether and it has also been found that the removal of the solvents from fluvastatin is very difficult by common methods such as air drying, vacuum drying, etc. No satisfactory results are obtained even for 10 days of drying. It has been now found that non-solvated amorphous fluvastatin sodium can easily be obtained just by performing the operations at a specific temperature range as described in the present invention.
We have discovered novel salts of fluvastatin such as barium and strontium and also discovered novel process for the preparation of substantially amorphous fluvastatin sodium, which is industrially feasible, with good quality.
One object of the present invention is to provide a barium salt of fluvastatin, process for its preparation and pharmaceutical composition comprising it.
Another object of the present invention is to provide a strontium salt of fluvastatin, process for its preparation and pharmaceutical composition comprising it.
The salt of the present invention may also serve as intermediates for preparation of substantially amorphous fluvastatin sodium and other polymorphs of fluvastatin sodium.
Yet another object of the present invention is to provide a novel process for the preparation of substantially amorphous fluvastatin sodium.
Summary of the Invention
In one aspect, the present invention provides a barium salt of fluvastatin, that is, fluvastatin barium.
In another aspect, the present invention provides a process for the preparation of fluvastatin barium, which comprises reacting methyl(±)-erythro-(E)-3,5-dihydroxy-7-[3'- (4"-fluorophenyl)-l'-(l"-methylethyl)indol-2'-yl]hept-6-enoate with barium hydroxide in suitable solvent to form fluvastatin barium.
In another aspect, the present invention provides a pharmaceutical composition comprising fluvastatin barium and a pharmaceutically acceptable excipient.
In another aspect, the present invention provides a strontium salt of fluvastatin, that is, fluvastatin strontium.
In another aspect, the present invention provides a process for the preparation of fluvastatin strontium, which comprises reacting methyl(±)-erythro-(E)-3,5-dihydroxy-7- [3 '-(4"-fluorophenyl)- 1 '-( 1 "-methylethyl)indol-2'-yl]hept-6-enoate with strontium hydroxide in suitable solvent to form fluvastatin strontium.
In another aspect, the present invention provides a pharmaceutical composition comprising fluvastatin strontium and a pharmaceutically acceptable excipient.
Yet another aspect, the present invention provides a novel process for the preparation substantially amorphous fluvastatin sodium, which comprises:
a) providing a solution of fluvastatin sodium in an ether solvent;
b) mixing one or more hydrocarbon solvents to the solution obtained in step (a) at above 35°C; and
c) isolating substantially amorphous fluvastatin sodium.
Brief Description of the Drawing
Figure 1 is X-ray powder diffraction spectrum of substantially amorphous fluvastatin barium.
Figure 2 is X-ray powder diffraction spectrum of substantially amorphous fluvastatin strontium.
Figure 3 is X-ray powder diffraction spectrum of substantially amorphous fluvastatin sodium.
X-ray powder diffraction spectrum was measured on a bruker axs D8 advance X- ray powder diffractometer having a copper-Κα radiation. Approximately 1 gm of sample was gently flattered on a sample holder and scanned from 2 to 50 degrees two-theta, at 0.02 degrees to theta per step and a step of 10.4 seconds. The sample was simply placed on the sample holder. The sample was rotated at 30 rpm at a voltage 40 KV and current 35 mA.
Detailed Description of the Invention
According to one aspect of the present invention, there is provided a barium salt of fluvastatin, that is, fluvastatin barium.
The term "fluvastatin barium" as used herein means any salt comprising fluvastatin anions and barium cations.
The fluvastatin barium may preferably be a solid such as amorphous or crystalline and more preferable solid is substantially amorphous fluvastatin barium.
The term "substantially amorphous fluvastatin barium" as used herein, refers to amorphous fluvastatin barium having about 35% w/w or less cr stallinity.
The powdered x-ray diffractogram (PXRD) of substantially amorphous fluvastatin barium is shown in figure 1.
According to another aspect of the present invention, there is provided a process for the preparation of fluvastatin barium, which comprises reacting methyl(±)-erythro- (E)-3,5-dihydroxy-7-[3'-(4"-fluorophenyl)-l'-(l"-methylethyl)indol-2'-yl]hept-6-enoate with barium hydroxide in suitable solvent to form fluvastatin barium.
Alternatively, fluvastatin barium may be prepared by a process which comprises reacting fluvastatin or its sodium salt with barium hydroxide in suitable solvent to form fluvastatin barium.
The suitable solvent used in the process may preferably be a solvent or mixture of solvents selected from the group consisting of water; an alcoholic solvent such as methanol, ethanol and isopropyl alcohol; an ester solvent such as ethyl acetate, methyl acetate, isopropyl acetate, tert-butyl methyl acetate and ethyl formate; acetonitrile; dimethylformamide; dimethylsulf oxide; an aromatic hydrocarbon solvent such as benzene, toluene and xylene; a halogenated hydrocarbon solvent such as methylene
chloride, chloroform,' carbontetrachloride and ethylene dichloride; a ketonic solvent such as acetone, methyl ethyl ketone, methyl isobutyl ketone and diethyl ketone; an ether solvent such as tetrahydrofuran, 1,4-dioxane, tert-butyl methyl ether and diethyl ether. More preferable solvent is water, an alcoholic solvent or a ketonic solvent, and still more preferable solvent is water, methanol, ethanol or isopropyl alcohol.
According to another aspect of the present invention, there is provided a pharmaceutical composition that comprises fluvastatin barium and pharmaceutically acceptable carriers, diluents or excipients and optionally other therapeutic ingredients. The salt may preferable be conveniently formulated into tablets, capsules, suspensions, dispersions, injectables and other pharmaceutical forms.
According to one aspect of the present invention, there is provided a strontium salt of fluvastatin, that is, fluvastatin strontium.
The term "fluvastatin strontium" as used herein means any salt comprising fluvastatin anions and strontium cations.
The fluvastatin strontium may preferably be a solid such as amorphous or crystalline and more preferable solid is substantially amorphous fluvastatin strontium.
The term "substantially amorphous fluvastatin strontium" as used herein, refers to amorphous fluvastatin strontium having about 50% w/w or less crystallinity
The powdered x-ray diffractogram (PXRD) of substantially amorphous fluvastatin strontium is shown in figure 2.
According to another aspect of the present invention, there is provided a process for the preparation of fluvastatin strontium, which comprises reacting methyl(±)-erythro- (E)-3,5-dihydroxy-7-[3'-(4"-fluorophenyl)- -(r'-methylethyl)indol-2'-yl]hept-6-enoate with strontium hydroxide in suitable solvent to form fluvastatin strontium.
Alternatively, fluvastatin strontium may be prepared by a process which comprises reacting fluvastatin or its sodium salt with strontium salt of an acid in suitable solvent to form fluvastatin strontium.
The suitable solvent used in the process may preferably be a solvent or mixture of solvents selected from the group consisting of water; an alcoholic solvent such as methanol, ethanol and isopropyl alcohol; an ester solvent such as ethyl acetate, methyl acetate, isopropyl acetate, tert-butyl methyl acetate and ethyl formate; acetonitrile;
dimethylformamide; dimethylsulfoxide; an aromatic hydrocarbon solvent such as benzene, toluene and xylene; a halogenated hydrocarbon solvent such as methylene chloride, chloroform, carbontetrachloride and ethylene dichloride; a ketonic solvent such as acetone, methyl ethyl ketone, methyl isobutyl ketone and diethyl ketone; an ether solvent such as tetrahydrofuran, 1,4-dioxane, tert-butyl methyl ether and diethyl ether. More preferable solvent is water, an alcoholic solvent or a ketonic solvent, and still more preferable solvent is water, methanol, ethanol or isopropyl alcohol.
According to another aspect of the present invention, there is provided a pharmaceutical composition that comprises fluvastatin strontium and pharmaceutically acceptable carriers, diluents or excipients and optionally other therapeutic ingredients. The salt may preferable be conveniently formulated into tablets, capsules, suspensions, dispersions, injectables and other pharmaceutical forms.
According to another aspect of the present invention, there is provided a novel process for the preparation of substantially amorphous fluvastatin sodium, which comprises:
a) providing a solution of fluvastatin sodium in an ether solvent;
b) mixing one or more hydrocarbon solvents to the solution obtained in step (a) at above 35°C; and
c) isolating substantially amorphous fluvastatin sodium.
The term "substantially amorphous fluvastatin sodium" as used herein, refers to amorphous fluvastatin sodium having about 25% w/w or less crystallinity.
The ether solvent used in step (a) may preferably be a solvent or mixture of solvents selected from tetrahydrofuran, methyl tetrahydrofuran, methyl tert-butyl ether, ethyl tert-butyl ether, 1 ,4-dioxane, diisopropyl ether, diethyl ether and tetrahydropyran. More preferable ether solvent is tetrahydrofuran and methyl tetrahydrofuran.
The reaction in step (b) may preferably be carried out at 40°C to boiling point of solvent or solvents and more preferably at 40 to 90°C.
The hydrocarbon solvents used in step (b) may preferably be selected from cyclohexane, n-hexane, heptane, benzene, toluene and xylene. More preferable hydrocarbon solvents are cyclohexane and heptane.
Order of addition of hydrocarbon solvent or solvents to the ether solution are not critical. The hydrocarbon solvent or solvents may be added to the ether solution or the ether solution may be added to hydrocarbon solvent or solvents.
The isolation of substantially amorphous fluvastatin sodium may preferably be performed by conventional techniques such as centrifugation and filtration.
The invention will now be further described by the following examples, which are illustrative rather than limiting.
Examples
Example 1: Preparation of substantially amorphous fluvastatin barium
Methyl(±)-erythro-(E)-3,5-dihydroxy-7-[3'-(4 -fluorophenyl)-l'-(r'-methylethyl) indol-2'-yl]hept-6-enoate (100 gm) was added to methanol (1000 ml) and stirred at 25 to 30°C. Barium hydroxide octahydrate (40 gm) was added to the above mixture at 25 to 30°C. The reaction mixture was stirred for 4 hours at 25 to 30°C, and then filtered. The solid obtained was washed with methanol and dried at 45 to 50°C for 4 hours to obtain 80 gm of substantially amorphous fluvastatin barium.
Example 2:
Fluvastatin (10 gm) was added to ethanol (100 ml) and barium hydroxide octahydrate (4 gm) at 25 to 30°C. The reaction mixture was stirred for 4 hours at 25 to 30°C, and then filtered. The solid obtained was washed with ethanol and dried at 45 to 50°C for 4 hours to obtain 8.5 gm of substantially amorphous fluvastatin barium.
Example 3:
Fluvastatin sodium (100 gm) was dissolved in methanol (1000 ml) at 25 to 30°C to get a clear solution. Barium hydroxide octahydrate (40 gm) was slowly added to the above solution at 25 to 30°C. The reaction mixture was stirred for 4 hours at 25 to 30°C, the obtained solid was filtered and washed with water. The solid was dried at 45 to 50°C for 4 hours to obtain 85 gm of substantially amorphous fluvastatin barium.
Example 4: Preparation of substantially amorphous fluvastatin strontium
Methyl(±)-erythro-(E)-3,5-dihydroxy-7-[3'-(4"-fluorophenyl)-r-(r'-methylethyl) indol-2'-yl]hept-6-enoate (100 gm) was added to methanol (1000 ml) and stirred at 25 to 30°C. Strontium hydroxide octahydrate (67 gm) was added to the above mixture at 25 to 30°C. The reaction mixture was stirred for 10 hours at 25 to 30°C, and then filtered. The solid obtained was washed with methanol and dried at 40 to 45 °C for 5 hours to obtain 73 gm of substantially amorphous fluvastatin strontium.
Example 5;
Fluvastatin (10 gm) was added to ethanol (100 ml) and strontium hydroxide octahydrate (6 gm) at 25 to 30°C. The reaction mixture was stirred for 10 hours at 25 to 30°C, and then filtered. The solid obtained was washed with ethanol and dried at 40 to 45°C for 5 hours to obtain 7 gm of substantially amoiphous fluvastatin strontium.
Example 6:
Fluvastatin sodium (100 gm) was dissolved in methanol (1000 ml) at 25 to 30°C to get a clear solution. Strontium hydroxide octahydrae (65 gm) was slowly added to the above solution at 25 to 30°C. The reaction mixture was stirred for 10 hours at 25 to 30°C, the obtained solid was filtered and washed with water. The solid was dried at 40 to 45°C for 5 hours to obtain 85 gm of substantially amorphous fluvastatin strontium. Example 7: Preparation of substantially amorphous fluvastatin sodium
Methyl(±)-erythro-(E)-3 ,5 -dihydroxy-7- [3 '-(4"-fluorophenyl)- Γ-( 1 "-methylethyl) indol-2'-yl]hept-6-enoate (100 gm), methanol (300 ml), sodium hydroxide (10 gm) and water (25 ml) are added at 25 to 30°C, and stirred to obtain a solution. Methylene chloride (1000 ml) was added to the solution and distilled off the solvent at 40°C under vacuum and then co-distilled with methyl tetrahydrofuran under nitrogen atmosphere to obtain residue. To the residue was added methyl tetrahydrofuran (300 ml) and then added slowly a mixture of heptane (750 ml) and cyclohexane (750 ml) under nitrogen atmosphere at 40 to 45°C. The reaction mass was stirred for 30 minutes at 40 to 45°C and filtered. The solid obtained was washed with a mixture of heptane and cyclohexane and then dried at 90°C under vacuum for 10 hours to obtain 100 gm of substantially
amorphous fluvastatin sodium (content of residual solvents: 112 ppm (parts per million) of cyclohexane; 175 ppm of heptane).
Example 8:
Methyl(±)-erythro-(E)-3,5-dihydroxy-7-[3'-(4"-fluorophenyl)-l,-(l"-methylethyl) indol-2'-yl]hept-6-enoate (100 gm), methanol (300 ml), sodium hydroxide (10 gm) and water (25 ml) are added at 25 to 30°C, and stirred to obtain a solution. Distilled off the solvent from the solution at 40°C under vacuum and then added water (1000 ml). The contents were heated to 50°C and then washed with ethyl acetate at 50°C, layers were separated. To the organic layer was added methylene chloride (2000 ml) at 25 to 30°C and pH of the reaction mass was adjusted to 7.0 with hydrochloric acid (50%, 50 ml) at 25 to 30°C. The methylene chloride layer were separated and washed with 10% sodium chloride solution. Distilled off the solvent at 40°C and then co-distilled with methyl tetrahydrofuran to obtain residue. To the residue was added methyl tetrahydrofuran (300 ml) and then added slowly a mixture of heptane (750 ml) and cyclohexane (750 ml) under nitrogen atmosphere at 40 to 45°C. The reaction mass was stirred for 30 minutes at 40 to 45°C and filtered. The solid obtained was washed with a mixture of heptane and cyclohexane and then dried at 90°C under vacuum for 10 hours to obtain 80 gm of substantially amorphous fluvastatin sodium (Content of residual solvents: 120 ppm of cyclohexane; 195 ppm of heptane).
Example 9:
Fluvastatin sodium crystalline form B (100 gm) was dissolved in methylene chloride (1000 ml) at room temperature. The contents were heated to reflux and were added methanol (250 ml) to obtain a solution. The solution was stirred for 15 minutes and filtered on hiflo-bed at 50°C, washed with methylene chloride. The filtrate obtained was distilled at below 40°C and co-distilled with tetrahydrofuran to obtain a residue. To the residue were added tetrahydrofuran (300 ml). The mixture of cyclohexane (750 ml) and heptane (750 ml) was heated to 80 to 85°C and then slowly added above reaction mass to this solution. The contents were maintained for 30 minutes at 80 to 85°C and then cooled to room temperature, maintained for 15 minutes at room temperature. The
solid obtained was collected by filtration, washed with a mixture of cyclohexane and heptane and then dried at 100°C under vacuum for 15 hours to obtain 90 gm of substantially amorphous fluvastatin sodium (Residual solvents are absent). Example 10:
Example 9 was repeated using fluvastatin sodium crystalline form XIV instead of fluvastatin sodium crystalline form B to obtain substantially amorphous fluvastatin sodium.
Example 11:
Example 9 was repeated using fluvastatin sodium crystalline form XXVI instead of fluvastatin sodium crystalline form B to obtain substantially amorphous fluvastatin sodium.
Example 12:
Fluvastatin barium (80 gm) was stirred with water (500 ml) and methylene chloride (1000 ml) at 25 to 30°C. The pH of the reaction mass was adjusted to 7.0 with hydrochloric acid (50%, 50 ml) and layers were separated. The organic layer was washed with sodium chloride (10%, 500 ml). Distilled off the solvent at 40°C under vacuum and co-distilled with tetrahydrofuran to obtain a residue. To the residue was added tetrahydrofuran (200 ml) and sodium hydroxide (7 gm) and then stirred for 30 minutes. To a mixture of heptane (525 ml) and cyclohexane (525 ml) was added slowly above reaction mass at 40 to 45°C under nitrogen atmosphere. The reaction mass was stirred for 30 minutes at 40 to 45°C. The solid obtained was collected by filtration, washed with a mixture of cyclohexane and heptane and then dried at 90°C under vacuum for 15 hours to obtain 60 gm of substantially amorphous fluvastatin sodium (Residual solvents are absent).
Example 13:
Fluvastatin strontium (50 gm) was stirred with water (300 ml) and methylene chloride (600 ml) at 25 to 30°C. The pH of the reaction mass was adjusted to 7.0 with hydrochloric acid (50%, 50 ml). The organic layer was separated and washed with
sodium chloride. Distilled off the solvent at 40 C under vacuum and co-distilled with tetrahydrofuran to obtain a residue. To the residue was added tetrahydrofuran (120 ml) and sodium hydroxide (4 gm) and then stirred for 30 minutes. To the mixture of heptane (320 ml) and cyclohexane (320 ml) was added slowly above reaction mass at 40 to 45°C under nitrogen atmosphere. The reaction mass was stirred for 30 minutes at 40 to 45°C. The solid obtained was collected by flirtation, washed with a mixture of cyclohexane and heptane and then dried at 90°C under vacuum for 15 hours to obtain 35 gm of substantially amorphous fluvastatin sodium (Residual solvents are absent).
Claims
1. A barium salt of fluvastatin.
2. The compound according to claim 1, wherein the barium salt of fluvastatin is solid.
3. The compound according to claim 2, wherein the solid is amorphous.
4. Substantially amorphous fluvastatin barium, characterized by an x-ray powder diffractogram as shown in figure 1.
5. A process for the preparation of fluvastatin barium, which comprises reacting methyl(±)-erytl ro-(E)-3 , 5 -dihydroxy-7- [3 '-(4"-fluorophenyl)- Γ-( 1 "-methylethyl) indol-2'-yl]hept-6-enoate with barium hydroxide in suitable solvent to form fluvastatin barium.
6. A process for the preparation of fluvastatin barium, which comprises reacting fluvastatin or its sodium salt with barium hydroxide in suitable solvent to form fluvastatin barium.
7. The process according to claims 5 and 6, wherein the suitable solvent is a solvent or mixture of solvents selected from the group consisting of water; an alcoholic solvent is methanol, ethanol and isopropyl alcohol; an ester solvent is ethyl acetate, methyl acetate, isopropyl acetate, tert-butyl methyl acetate and ethyl formate; acetonitrile; dimethylformamide; dimethylsulfoxide; an aromatic hydrocarbon solvent is benzene, toluene and xylene; a halogenated hydrocarbon solvent is methylene chloride, chloroform, carbontetrachloride and ethylene dichloride; a ketonic solvent is acetone, methyl ethyl ketone, methyl isobutyl ketone and diethyl ketone; an ether solvent is tetrahydrofuran, 1 ,4-dioxane, tert-butyl methyl ether and diethyl ether.
8. The process according to claim 4, wherein the solvent is water, an alcoholic solvent or a ketonic solvent.
9. The process according to claim 5, wherein the solvent is water, methanol, ethanol or isopropyl alcohol.
10. A strontium salt of fluvastatin.
11. The compound according to claim 10, wherein the strontium salt of fluvastatin is solid.
12. The compound according to claim 11, wherein the solid is amorphous.
13. Substantially amorphous fluvastatin strontium, characterized by an x-ray powder diffractogram as shown in figure 2.
14. A process for the preparation of fluvastatin strontium, which comprises reacting methyl(±)-erythro-(E)-3,5-dihydroxy-7-[3'-(4 -fluorophenyl)-r-(r'-methylethyl) indol-2'-yl]hept-6-enoate with strontium hydroxide in suitable solvent to form fluvastatin strontium.
15. A process for the preparation of fluvastatin strontium, which comprises reacting fluvastatin or its sodium salt with strontium salt of an acid in suitable solvent to form fluvastatin strontium.
16. The process according to claims 14 and 15, wherein the suitable solvent is a solvent or mixture of solvents selected from the group consisting of water; an alcoholic solvent is methanol, ethanol and isopropyl alcohol; an ester solvent is ethyl acetate, methyl acetate, isopropyl acetate, tert-butyl methyl acetate and ethyl formate; acetonitrile; dimethylformamide; dimethylsulfoxide; an aromatic hydrocarbon solvent is benzene, toluene and xylene; a halogenated hydrocarbon solvent is methylene chloride, chloroform, carbontetrachloride and ethylene dichloride; a ketonic solvent is acetone, methyl ethyl ketone, methyl isobutyl ketone and diethyl ketone; an ether solvent is tetrahydrofuran, 1,4-dioxane, tert-butyl methyl ether and diethyl ether.
17. The process according to claim 16, wherein the solvent is water, an alcoholic solvent or a ketonic solvent.
18. The process according to claim 17, wherein the solvent is water, methanol, ethanol or isopropyl alcohol.
19. A process for the preparation of substantially amorphous fluvastatin sodium, which comprises:
a) providing a solution of fluvastatin sodium in an ether solvent;
b) mixing one or more hydrocarbon solvents to the solution obtained in step (a) at above 35°C; and
c) isolating substantially amorphous fluvastatin sodium.
20. The process according to claim 19, wherein the ether solvent used in step (d) is a solvent or mixture of solvents selected from tetrahydrofuran, methyl tetrahydrofuran, methyl tert-butyl ether, ethyl tert-butyl ether, 1,4-dioxane, diisopropyl ether, diethyl ether and tetrahydropyran.
21. The process according to claim 20, wherein the ether solvent is tetrahydrofuran and methyl tetrahydrofuran.
22. The process according to claim 19, wherein the reaction in step (b) is carried out at 40°C to boiling point of the solvent or solvents.
23. The process according to claim 22, wherein the reaction is carried out at 40°C to 90°C.
24. The process according to claim 19, wherein the hydrocarbon solvents used in step (e) are selected from cyclohexane, n-hexane, heptane, benzene, toluene and xylene.
25. The process according to claim 24, wherein the hydrocarbon solvents are cyclohexane and heptane.
26. A pharmaceutical composition that comprises fluvastatin barium and pharmaceutically acceptable carriers, diluents or excipients and optionally other therapeutic ingredients .
27. The pharmaceutical composition as claimed in claim 26, wherein the salt is conveniently formulated into tablets, capsules, suspensions, dispersions, injectables and other pharmaceutical forms.
28. A pharmaceutical composition that comprises fluvastatin strontium and pharmaceutically acceptable carriers, diluents or excipients and optionally other therapeutic ingredients.
29. The pharmaceutical composition as claimed in claim 28, wherein the salt is conveniently formulated into tablets, capsules, suspensions, dispersions, injectables and other pharmaceutical forms.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/IN2010/000189 WO2011117875A1 (en) | 2010-03-26 | 2010-03-26 | Salts of fluvastatin and process for the preparation of substantially amorphous fluvastatin sodium |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/IN2010/000189 WO2011117875A1 (en) | 2010-03-26 | 2010-03-26 | Salts of fluvastatin and process for the preparation of substantially amorphous fluvastatin sodium |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2011117875A1 true WO2011117875A1 (en) | 2011-09-29 |
Family
ID=44672505
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/IN2010/000189 WO2011117875A1 (en) | 2010-03-26 | 2010-03-26 | Salts of fluvastatin and process for the preparation of substantially amorphous fluvastatin sodium |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2011117875A1 (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080146817A1 (en) * | 2003-06-18 | 2008-06-19 | Teva Pharmaceuticals Usa, Inc. | Fluvastatin sodium crystal forms, processes for preparing them, compositions containing them and methods of using them |
| US20090099154A1 (en) * | 2005-06-29 | 2009-04-16 | Panacea Biotec Ltd. | Pharmaceutical Sustained Release Compositions and Processes Thereof |
| US20090263453A1 (en) * | 2008-04-18 | 2009-10-22 | Warsaw Orthopedic, Inc. | Methods and Compositions for Treating Pain Comprising a Statin |
-
2010
- 2010-03-26 WO PCT/IN2010/000189 patent/WO2011117875A1/en active Application Filing
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080146817A1 (en) * | 2003-06-18 | 2008-06-19 | Teva Pharmaceuticals Usa, Inc. | Fluvastatin sodium crystal forms, processes for preparing them, compositions containing them and methods of using them |
| US20090099154A1 (en) * | 2005-06-29 | 2009-04-16 | Panacea Biotec Ltd. | Pharmaceutical Sustained Release Compositions and Processes Thereof |
| US20090263453A1 (en) * | 2008-04-18 | 2009-10-22 | Warsaw Orthopedic, Inc. | Methods and Compositions for Treating Pain Comprising a Statin |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7687642B2 (en) | Fluvastatin sodium crystal forms, processes for preparing them, compositions containing them and methods of using them | |
| US20060160785A1 (en) | Ezetimibe polymorphs | |
| US20090182008A1 (en) | Crystalline forms of pitavastatin calcium | |
| US20080167477A1 (en) | Novel polymorphic forms of carvedilol dihydrogen phosphate and process for preparing the same | |
| KR20130038258A (en) | Saxagliptin intermediates, saxagliptin polymorphs, and processes for preparation thereof | |
| EP2103612A1 (en) | Crystalline forms of palonosetron hydrochloride | |
| EP2046777A2 (en) | Amorphous eletriptan hydrobromide and process for preparing it and other forms of eletriptan hydrobromide | |
| US20150051228A1 (en) | Amorphous form of linagliptin and process for preparation thereof | |
| US7368468B2 (en) | Fluvastatin sodium crystal forms XIV, LXXIII, LXXIX, LXXX and LXXXVII, processes for preparing them, compositions containing them and methods of using them | |
| WO2008026216A2 (en) | Process for purification of aprepitant | |
| US20100260851A1 (en) | Novel Polymorph of Atorvastatin Calcium and Use Thereof for the Preparation of Amorphous Atorvastatin Calcium | |
| WO2011117875A1 (en) | Salts of fluvastatin and process for the preparation of substantially amorphous fluvastatin sodium | |
| KR20100014728A (en) | Ibandronate sodium polymorphs | |
| WO2017167949A1 (en) | Crystalline forms of bilastine | |
| WO2007084697A2 (en) | Process for preparing a crystalline form of tegaserod maleate | |
| US20080027125A1 (en) | Fluvastatin sodium novel forms and preparation thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10848302 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 10848302 Country of ref document: EP Kind code of ref document: A1 |